---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-135024"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:33:54.808526+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AlloVir reports Q1 net loss $41.2M; Phase 3 posoleucel trials on track for 2024

## Summary
- Net loss of $41.2M ($0.44/share) vs $43.9M ($0.69/share) in Q1 2022.
- Cash, cash equivalents and short-term investments were $202.6M as of March 31, 2023.
- R&D expenses $30.7M, G&A $12.5M; FY 2023 operating expense guidance $150M-$170M excl. non-cash.
- Three Phase 3 registrational trials of posoleucel in allo-HCT patients continue enrolling; data readouts expected in 2024.
- Positive Phase 2 data for posoleucel in BK viremia in kidney transplant recipients to be presented at ATC 2023.

## SEC filing metadata
- accession: 0001193125-23-135024
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312523135024/0001193125-23-135024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312523135024/d277750d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-135024
- JSON: https://secwatch.observer/filing/0001193125-23-135024.json
- Plain text: https://secwatch.observer/filing/0001193125-23-135024.txt

## Key facts
- Earnings Releases
  Kalaris Therapeutics, Inc. updated its fiscal year 2023 guidance (initiated).
  - Period: fiscal year 2023
  - Guidance: initiated
  - Result: guidance update
  source text: For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523135024/0001193125-23-135024-index.htm
- Earnings Releases
  Kalaris Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $41.2 million, EPS $0.44 per share.
  - Period: the first quarter ended March 31, 2023
  - Net income: $41.2 million
  - EPS: $0.44 per share
  - Result: reported results
  source text: For the quarter ended March 31, 2023, net loss was $41.2 million or $0.44 per share compared with a net loss of $43.9 million or $0.69 per share for the quarter ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523135024/0001193125-23-135024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.